What to Expect at the 3rd ADC Toxicity Summit
The 3rd ADC Toxicity Summit is returning with a focus on improving the translation of toxicities between preclinical and clinical studies with both forward and reverse translation.
Join us for a variety of critical sessions ranging from maximizing the translational relevance of preclinical models, meeting regulatory expectations for these models, exploring novel payload toxicities and hearing clinical perspectives from the leading clinicians and oncologists.
Develop a comprehensive understanding on how emerging ADC designs, ADME characterization, and linker technologies can impact safety profiles to widen your ADC therapeutic window and learn from leading clinicians on how specific patients are being affected and the mitigation strategies for intolerable toxicities.
Brand New Agenda
Featuring industry insights from leading clinicians, toxicologists, and preclinical and translational scientists, this pivotal moment of ADCs to make meaningful strides forward in developing safer ADCs to advance them to clinic and improve patient outcomes.
Top 5 Takeaways:
1
2
3
4
5
Evaluate the emerging ADC designs and how you can leverage ADME characterization of linker payloads to minimize toxicity with Iksuda and Johnson & Johnson
Maximize the translational relevance of in vivo models such as rodent IV infusion models for increased efficiency and reduced costs with AbbVie and MacroGenics
Overcome the limitations of in vitro and preclinical models with targeted delivery, patient-derived xenograft (PDX) models, and the use of computational modelling with AI with AbbVie, AstraZeneca, and Mayo Clinic
Gain invaluable insights into optimizing ADC dosing by tackling dose-limiting toxicities early in development with Takeda and Heidelberg Pharma
Bridge the gap between preclinical and clinical studies by engaging with the leading ADC Clinicians and Toxicity Specialists – delve deeper into toxicities such as ILD, Hepatoxicity, Neurotoxicity, Cardiotoxicity, Ocular toxicity, and more
Who Will You Meet?
Join over 80+ experts spanning toxicology, pathology, translational sciences, preclinical development, pharmacology, and biology at this exclusive gathering, fostering profound discussions aimed at advancing the development of safer ADCs. This niche community is connecting over 3 days to leverage collective expertise and to drive progress in the prevention of toxicities.
What Your Peers Are Excited For:
“The conference focused on a critical topic which is not adequately covered in published literature. The speakers covered both program specific and more general aspects of ADC toxicity. Companies are often not willing to discuss toxicity but the speakers disclosed previously unpublished aspects of their work. Overall a very worthwhile three days.” - Vice President, Oncology, Bicycle Therapeutics
“This was a great conference and was a nice size which facilitated lots of networking and interaction.” - Team Leader, Almac
“It was a great opportunity to exchanges with peers in the field of ADC development and with experts in the field.” - Managing Director, Mablink
“Real tox data influencing the drug development, and retrospective analysis for tox events and drug development” - Senior Director, Toxicology, Mersana
